Earendil Labs Raises USD 787m to Advance AI-Driven Biologics Discovery and Development Pipeline

# Earendil Labs Raises USD 787m to Advance AI-Driven Biologics Pipeline Earendil Labs, a Wilmington, Delaware-headquartered biotechnology company focused on AI-driven biologics discovery and development, has closed USD 787 million in financing. The Earendil Labs funding will support the expansion of the company's computational platform and advance a pipeline of antibody and biologics programs targeting autoimmune diseases, cancer, and other indications, the company said. The round drew participation from Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, and the Biotech Development Fund, a vehicle created by Hillhouse and Pfizer. Additional existing and new technology- and healthcare-focused investors also participated. The company did not disclose the specific series designation of the round. Earendil Labs said it plans to use the capital to scale its research and development operations, expand interdisciplinary teams across science, engineering, and translational medicine, advance multiple internal programs toward clinical milestones, and deepen strategic partnerships. Earendil Labs describes its platform as an AI-native engine that integrates artificial intelligence across the full lifecycle of biologics research and development, from target identification through candidate design, optimization, and clinical progression. The platform is built around computational approaches to protein engineering, enabling the generation and multi-parameter optimization of antibody-based therapeutics. The company said the platform has produced more than 40 programs to date, spanning multiple disease areas and modalities including half-life extended antibodies and bispecific antibodies. The company's lead candidate is HXN-1001, a half-life extended anti-TL1A antibody that Earendil Labs said is ready for Phase 2 clinical development. TL1A is a cytokine implicated in inflammatory and autoimmune pathology, and several companies are pursuing anti-TL1A approaches across indications including inflammatory bowel disease. Additional IND submissions are planned for 2026 and 2027, though the company has not disclosed specific candidates or indications beyond its lead program and two partnered assets. Those partnered assets, HXN-1002 and HXN-1003, are next-generation bispecific antibodies for autoimmune and inflammatory bowel diseases. In 2025, Earendil Labs entered a worldwide exclusive license agreement with [Sanofi](https://www.sanofi.com) covering both candidates. More recently, the two companies expanded their relationship through a broader strategic collaboration applying Earendil Labs' discovery platform to multiple autoimmune and inflammatory disease programs. Financial terms of neither arrangement have been disclosed. Earendil Labs was founded by Jian Peng, PhD, who serves as CEO, and Zhenping Zhu, MD, PhD, who serves as co-founder, president, and co-CEO. The company also operates through an affiliate, Helixon Therapeutics. The available information does not indicate that the company's platform technology was spun out of or licensed from a research university; the platform appears to have been developed internally by the founding team. Details regarding the founders' prior academic affiliations or institutional research origins are not specified in the company's public disclosures. No details of previous funding rounds held by Earendil Labs were provided in the company's announcement. The USD 787 million raise represents the only financing event disclosed in the current press release. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/earendil-labs-funding-raises-usd-787m-to-advance)